tiprankstipranks
Sangamo Therapeutics (SGMO)
NASDAQ:SGMO
US Market

Sangamo Therapeutics (SGMO) Stock Forecast & Price Target

2,622 Followers
See the Price Targets and Ratings of:

SGMO Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
1 Buy
1 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Sangamo
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SGMO Stock 12 Month Forecast

Average Price Target

$6.00
▲(1900.00% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Sangamo Therapeutics in the last 3 months. The average price target is $6.00 with a high forecast of $10.00 and a low forecast of $2.00. The average price target represents a 1900.00% change from the last price of $0.30.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.26,1.0092307692307694,1.7584615384615385,2.5076923076923077,3.2569230769230773,4.006153846153846,4.7553846153846155,5.504615384615384,6.253846153846154,7.003076923076923,7.752307692307692,8.50153846153846,9.250769230769231,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.26,0.7015384615384616,1.143076923076923,1.5846153846153845,2.0261538461538464,2.4676923076923076,2.909230769230769,3.350769230769231,3.792307692307692,4.233846153846154,4.6753846153846155,5.116923076923077,5.558461538461538,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.26,0.39384615384615385,0.5276923076923077,0.6615384615384615,0.7953846153846154,0.9292307692307692,1.063076923076923,1.1969230769230768,1.3307692307692307,1.4646153846153844,1.5984615384615384,1.7323076923076923,1.866153846153846,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.57,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.741,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.472,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.536,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.561,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.539,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.674,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.598,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.425,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.42,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.567,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.429,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.26,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$10.00Average Price Target$6.00Lowest Price Target$2.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on SGMO
H.C. Wainwright
H.C. Wainwright
$10
Buy
3233.33%
Upside
Reiterated
04/02/26
Sangamo Therapeutics: Partnering-Driven Path to 2027 Fabry Gene Therapy Launch Supports Buy Rating and $10 Target
RBC Capital Analyst forecast on SGMO
RBC Capital
RBC Capital
$2
Hold
566.67%
Upside
Reiterated
03/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Terns Pharmaceuticals (NASDAQ: TERN), Sangamo Therapeutics (NASDAQ: SGMO) and Galectin Therapeutics (NASDAQ: GALT)
Wells Fargo Analyst forecast on SGMO
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$4$2
Hold
566.67%
Upside
Reiterated
01/05/26
Sangamo Biosciences (SGMO) Receives a Hold from Wells Fargo
Barclays Analyst forecast on SGMO
Barclays
Barclays
$5$1
Hold
233.33%
Upside
Downgraded
11/07/25
Sangamo Biosciences (SGMO) was downgraded to a Hold Rating at Barclays
TD Cowen Analyst forecast on SGMO
TD Cowen
TD Cowen
Buy
Reiterated
08/11/25
Sangamo Biosciences: Strategic Positioning and Growth Potential Drive Buy Rating
Jefferies
$2$1.5
Buy
400.00%
Upside
Reiterated
05/13/25
Sangamo BioSciences (SGMO) PT Lowered to $1.50 at JefferiesJefferies analyst Maury Raycroft lowered the price target on Sangamo BioSciences (NASDAQ: SGMO) to $1.50 (from $2.00) while maintaining a Buy rating.
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on SGMO
H.C. Wainwright
H.C. Wainwright
$10
Buy
3233.33%
Upside
Reiterated
04/02/26
Sangamo Therapeutics: Partnering-Driven Path to 2027 Fabry Gene Therapy Launch Supports Buy Rating and $10 Target
RBC Capital Analyst forecast on SGMO
RBC Capital
RBC Capital
$2
Hold
566.67%
Upside
Reiterated
03/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Terns Pharmaceuticals (NASDAQ: TERN), Sangamo Therapeutics (NASDAQ: SGMO) and Galectin Therapeutics (NASDAQ: GALT)
Wells Fargo Analyst forecast on SGMO
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$4$2
Hold
566.67%
Upside
Reiterated
01/05/26
Sangamo Biosciences (SGMO) Receives a Hold from Wells Fargo
Barclays Analyst forecast on SGMO
Barclays
Barclays
$5$1
Hold
233.33%
Upside
Downgraded
11/07/25
Sangamo Biosciences (SGMO) was downgraded to a Hold Rating at Barclays
TD Cowen Analyst forecast on SGMO
TD Cowen
TD Cowen
Buy
Reiterated
08/11/25
Sangamo Biosciences: Strategic Positioning and Growth Potential Drive Buy Rating
Jefferies
$2$1.5
Buy
400.00%
Upside
Reiterated
05/13/25
Sangamo BioSciences (SGMO) PT Lowered to $1.50 at JefferiesJefferies analyst Maury Raycroft lowered the price target on Sangamo BioSciences (NASDAQ: SGMO) to $1.50 (from $2.00) while maintaining a Buy rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sangamo Therapeutics

3 Months
xxx
Success Rate
8/16 ratings generated profit
50%
Average Return
+9.53%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +9.53% per trade.
1 Year
Ritu BaralTD Cowen
Success Rate
5/16 ratings generated profit
31%
Average Return
+18.46%
Copying Ritu Baral's trades and holding each position for 1 Year would result in 31.25% of your transactions generating a profit, with an average return of +18.46% per trade.
2 Years
xxx
Success Rate
2/21 ratings generated profit
10%
Average Return
-34.99%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 9.52% of your transactions generating a profit, with an average return of -34.99% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SGMO Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
3
2
1
2
3
Buy
0
0
0
0
0
Hold
2
3
1
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
5
2
4
4
In the current month, SGMO has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. SGMO average Analyst price target in the past 3 months is 6.00.
Each month's total comprises the sum of three months' worth of ratings.

SGMO Financial Forecast

SGMO Earnings Forecast

The previous quarter’s earnings for SGMO were -$0.11.
The previous quarter’s earnings for SGMO were -$0.11.

SGMO Sales Forecast

The previous quarter’s earnings for SGMO were $14.23M.
The previous quarter’s earnings for SGMO were $14.23M.

SGMO Stock Forecast FAQ

What is SGMO’s average 12-month price target, according to analysts?
Based on analyst ratings, Sangamo Therapeutics’s 12-month average price target is 6.00.
    What is SGMO’s upside potential, based on the analysts’ average price target?
    Sangamo Therapeutics has 1900.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SGMO a Buy, Sell or Hold?
          Sangamo Therapeutics has a consensus rating of Moderate Buy which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Sangamo Therapeutics’s price target?
            The average price target for Sangamo Therapeutics is 6.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $10.00 ,the lowest forecast is $2.00. The average price target represents 1900.00% Increase from the current price of $0.3.
              What do analysts say about Sangamo Therapeutics?
              Sangamo Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of SGMO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.